Skip to main content

Table 1 Different N-glycan structures and relative intensities for the native and two recombinant preparations of G-hPRL

From: Expression of glycosylated human prolactin in HEK293 cells and related N-glycan composition analysis

  N-Glycan Underivatized mass (–H2O) (Da) Relative intensity of each N-glycan per each preparation (%)
HEK-G-hPRL CHO-G-hPRL Pit-G-hPRL
1 0 892.3 3.9
2 F1 1038.4 8.2
3 M1 1054.4 0.4
4 M2 1216.4 9.0 4.6 0.7
5 N1F1 1241.5 5.8 0.3
6 N2F1(-M) 1282.5 4.5
7 M2P1 1296.4 1.1
8 M3 1378.5 1.0 0.5
9 N1G1F1 1403.5 0.4
10 N2F1 1444.5 11.0 0.5
11 M3P1 1458.5 7.6 3.1
12 N3 1501.6 3.5
13 N1G1M2 1581.6 3.0
14 N2F2 1590.6 0.5
15 N2G1F1 1606.6 4.1 1.3 0.5
16 N2G2 1622.6 2.7
17 N3F1/N2Gn1F1 1647.6 9.4 0.6
18 N3G1 1663.6 2.9
19 M1N1Gn1F1(SO4)1 1686.6 3.2
20 N1G1S1F1 1694.6 0.9 0.6
21 M1N1G1S1 1710.6 1.1
22 N2Gn1F1(SO4)1 1727.6 1.8
23 N2G1F2 1752.7 2.6 0.8
24 N2G2F1 1768.6 2.4 5.0
25 N2G3 1784.6 3.3
26 N2Gn1F2 1793.7 1.4
27 N3G1F1 1809.7 4.2
28 N1S2F1 1823.6 2.9
29 N4F1 1850.7 4.3
30 N2G1Gn1F1(SO4)1 1889.6 1.3
31 N2G1S1F1 1897.7 0.6
32 N2G2S1 1913,7 1.8 1.8
33 N2G2F2 1914.7 2.1 0.5
34 N2Gn2F1(SO4)1 1930.6 4.1
35 N2G4 1946.7 1.6
36 N3G1F2 1955.7 2.7
37 N1S2F2 1969.7 2.7
38 N3G2F1 1971.7 1.8
39 N3G3 1987.7 1.6
40 N4F2 1996.7 3.2
41 N2Gn2F2 1996.8 0.6
42 N2Gn2F1(SO4)2 2010.6 28.1
43 N4G1F1 2012.8 1.7
44 N2G1Gn1F2(SO4)1 2035.7 1.7
45 N2G2S1F1 2059.7 12.0 0.5
46 N2G2F3 2060.8 1.4
47 N2G3S1 2075.7 1.6
48 N2Gn2F2(SO4)1 2076.7 33.8
49 N3G2S1 2116.8 2.4
50 N2Gn2F3 2142.8 0.5
51 N2G2S2 2204.8 6.9
52 N2G2S2F1 2350.8 56.1 0.6
53 N3G3S2F1 2715,9 0.8
54 N3G3S3 2861.0 0.3
  Number of N-glycan structures n = 28 n = 14 n = 28
  Fucosylated glycans (%) 66.8 76.7 90.5
  Sialylated glycans (%) 11.4 80.5 1.7
  Sulfated glycans (%) 74.0
  1. Abbreviations for N-glycans were made by not considering the basic pentasaccharide nucleus (“zero”) and adding all other monosaccharides, as stated in Table 1 and Fig. 6, in the following order: Man (M); GlcNAc (N); Gal (G); GalNAc (Gn); NeuAc/sialic acid (S); Fuc (F). So, for example, NeuAc1 Gal1 GlcNAc2 Fuc1 + Man3 GlcNAc2, becomes N2G1S1F1 (Capone et al. 2015)